Endurant Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Endurant Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-31,349	Closed	-$2.33M	–	67
2022 Q2	$2.33M	Sell	31,349 -15,091	-32%	-$1.13M	0.82%	32
2022 Q1	$4.17M	Sell	46,440 -2,466	-5%	-$228K	1.1%	25
2021 Q4	$5.48M	Buy	+48,906	New	+$5.9M	1.32%	24
2017 Q4	–	Sell	-6,300	Closed	-$545K	–	91
2017 Q3	$545K	Buy	6,300 +3,000	+91%	+$241K	0.17%	79
2017 Q2	$255K	Sell	3,300 -200	-6%	-$14.2K	0.07%	91
2017 Q1	$243K	Buy	+3,500	New	+$235K	0.08%	84

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Endurant Capital Management's XBI Position: Q3 2022 in Review

Endurant Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 31,349 shares — an estimated $2.33M sold.

Endurant Capital Management first reported a position in XBI in Q1 2017 and held it in 6 quarters. The position peaked at $5.48M in Q4 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Endurant Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
Endurant Capital Management sold 31,349 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $2.33M.
Endurant Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 6 quarters.
Endurant Capital Management's State Street SPDR S&P Biotech ETF position peaked at $5.48M in Q4 2021.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.